Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215429 · ClinicalTrials.gov registry record
SpO2 Validation Study-Philips Optimus
A clinical trial, sponsored by Philips Clinical & Medical Affairs Global.
- Terminated
- Registry status
- 24
- Enrollment target
NCT07215429: Clinical Trial study, sponsored by Philips Clinical & Medical Affairs Global.
NCT07215429 is a clinical trial that was terminated before completion, run by Philips Clinical & Medical Affairs Global. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215429 was terminated before completion, sponsored by Philips Clinical & Medical Affairs Global.
- TERMINATED
- Registry status
- 24 participants
- Enrollment target
Study Summary
Validation study to validate the SpO2 accuracy performance of the Sponsor's SpO2 sensors over the range of 70-100% SaO2 during non-motion conditions assessed by CO-Oximetry
Primary Outcome
Pulse Oximetry Subsystem during non-motion conditions over the range of 70-100% SaO2, when compared with the reference SaO2 obtained from CO-Oximetry analysis of arterial blood samples.
Interventions
- DEVICE No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-09-09 |
| Est. Completion | 2025-09-19 |
Why NCT07215429 stopped before completion
NCT07215429 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 24 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT07215429 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07215429 about?
NCT07215429 is a clinical study titled "SpO2 Validation Study-Philips Optimus". Validation study to validate the SpO2 accuracy performance of the Sponsor's SpO2 sensors over the range of 70-100% SaO2 during non-motion conditions assessed by CO-Oximetry
What is the current status of trial NCT07215429?
This trial is currently terminated. The enrollment target is 24 participants. The study started on 2025-09-09. Estimated completion is 2025-09-19.
What interventions are being tested in trial NCT07215429?
The interventions under investigation include: No intervention (DEVICE).
Who is sponsoring clinical trial NCT07215429?
This trial is sponsored by Philips Clinical & Medical Affairs Global, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI